Sanofi Consumer Health care India Limited reported revenue of ₹2,631 million for the third quarter of 2026, registering a 12% year-on-year growth, driven by a 19% increase in domestic sales and improved performance across key brands.
The company’s profit before tax rose 22% year-on-year to ₹1,027 million during the quarter, while earnings per share increased by ₹5.95, also marking a 22% growth. Managing Director Himanshu Bakshi attributed the performance to disciplined strategy execution, volume expansion and market share gains. He said investments in brand building, distribution expansion and engagement with health care professionals were helping the company reach more consumers.
For the nine months ended 2026, revenue from operations grew 16% year-on-year to ₹7,280 million. Domestic sales increased 15%, supported by a relaunch, while export sales rose 19%. Profit before tax for the nine-month period increased 24%.
In Kolkata, the growth in domestic sales highlights the potential of consumer health care products in urban and regional markets, including allergy management, digestive wellness, pain care and multi vitamins. Distribution expansion and stronger brand engagement could support product availability and consumer access across retail pharmacies and health care outlets in the city.
Sanofi Consumer Health care India became a separate legal entity following its demerger from Sanofi India Limited on June 1, 2024. Its key brands include Allegra, De PURA, Avil and Combiflam.
